Patents by Inventor Myoung Ki Baek
Myoung Ki Baek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230051318Abstract: The present invention relates to a compound represented by Formula 1 wherein A, B, L, X, and R1 to R6 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.Type: ApplicationFiled: December 1, 2020Publication date: February 16, 2023Inventors: Han Kyu LEE, Jeong-Un HWANG, Kyu-Hwan LEE, Hyung-Ho CHOI, Jung-In JANG, Hyuck-Joo LEE, Seung-Tae KANG, Hyun-Ho YOON, Neul HA, Hyun-Hwa LA, Jin Woong KIM, Dae Hoon KIM, Myoung Ki BAEK
-
Publication number: 20210085646Abstract: The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.Type: ApplicationFiled: December 14, 2017Publication date: March 25, 2021Applicant: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Myoung Ki BAEK, So Young CHOI, Ji Hye LEE
-
Publication number: 20190314336Abstract: The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.Type: ApplicationFiled: December 14, 2017Publication date: October 17, 2019Inventors: Myoung Ki BAEK, Ji Hye LEE, So Young CHOI
-
Publication number: 20180221383Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Myoung-Ki BAEK, Jae-Hoon JO, Hye-Jin CHANG
-
Patent number: 9962392Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: GrantFiled: October 23, 2013Date of Patent: May 8, 2018Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Patent number: 9724335Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: GrantFiled: December 29, 2016Date of Patent: August 8, 2017Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Myoung Ki Baek, Augustin Pegan
-
Publication number: 20170151258Abstract: The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.Type: ApplicationFiled: June 30, 2016Publication date: June 1, 2017Inventors: Gary Bream, Moise A. Khayrallah, Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Publication number: 20170105973Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: ApplicationFiled: December 29, 2016Publication date: April 20, 2017Inventors: Myoung Ki BAEK, Augustin PEGAN
-
Patent number: 9566268Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: GrantFiled: August 8, 2016Date of Patent: February 14, 2017Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Myoung Ki Baek, Augustin Pegan
-
Publication number: 20160346258Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: ApplicationFiled: August 8, 2016Publication date: December 1, 2016Inventors: Myoung Ki BAEK, Augustin PEGAN
-
Patent number: 9439970Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: GrantFiled: November 7, 2013Date of Patent: September 13, 2016Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Myoung Ki Baek, Augustin Pegan
-
Publication number: 20150283243Abstract: The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-ben-zyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.Type: ApplicationFiled: November 7, 2013Publication date: October 8, 2015Inventors: Myoung Ki Baek, Augustin Pegan
-
Publication number: 20140128381Abstract: The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Inventors: Gary Bream, Moise A. Khayrallah, Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Publication number: 20140051690Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: SK Biopharmaceuticals Co., Ltd.Inventors: Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Patent number: 8592406Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: GrantFiled: November 5, 2010Date of Patent: November 26, 2013Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Publication number: 20120252793Abstract: The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Inventors: Gary Bream, Moise A. Khayrallah, Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Publication number: 20120190670Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anti-convulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: ApplicationFiled: November 5, 2010Publication date: July 26, 2012Inventors: Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Publication number: 20110172211Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anti-convulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant.Type: ApplicationFiled: November 5, 2010Publication date: July 14, 2011Inventors: Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
-
Patent number: 7745430Abstract: Disclosed herein is a transnasal anticonvulsive pharmaceutical composition comprising diazepam as an active ingredient, water, a fatty acid ester, diethylene glycol monoethyl ether, ethanol and sodium glycocholate, wherein the weight of the fatty acid ester is at least 2-fold higher than that of water and is at least 2-fold higher than that of ethanol. The anticonvulsive pharmaceutical composition for transmucosal delivery of diazepam according to the present invention includes a minimized content of water and ethanol, a fatty acid ester as a main ingredient and no use of a polar solvent, e.g. glycol, and, exhibits improved diazepam solubility and transmucosal permeability due to using a small amount of water and ethanol. The present invention also includes treatment of convulsions by transnasally administering to a patient in need thereof a therapeutically effective amount of the disclosed compositions.Type: GrantFiled: November 15, 2006Date of Patent: June 29, 2010Assignee: SK Holdings Co., Ltd.Inventors: Kwon Ho Kim, Paramjeet Kaur, Jae Hoon Jo, Myoung Ki Baek, Yeo Joo Yuk
-
Publication number: 20080113970Abstract: Disclosed herein is a transnasal anticonvulsive pharmaceutical composition comprising diazepam as an active ingredient, water, a fatty acid ester, diethylene glycol monoethyl ether, ethanol and sodium glycocholate, wherein the weight of the fatty acid ester is at least 2-fold higher than that of water and is at least 2-fold higher than that of ethanol. The anticonvulsive pharmaceutical composition for transmucosal delivery of diazepam according to the present invention includes a minimized content of water and ethanol, a fatty acid ester as a main ingredient and no use of a polar solvent, e.g. glycol, and, exhibits improved diazepam solubility and transmucosal permeability due to using a small amount of water and ethanol. The present invention also includes treatment of convulsions by transnasally administering to a patient in need thereof a therapeutically effective amount of the disclosed compositions.Type: ApplicationFiled: November 15, 2006Publication date: May 15, 2008Inventors: Kwon Ho Kim, Paramjeet Kaur, Jae Hoon Jo, Myoung Ki Baek, Yeo Joo Yuk